A randomized, double‐blind, dose‐controlled study of the use of dexmedetomidine alone for procedural sedation of children and adolescents undergoing MRI scans

Author:

Khan Umar1,Hammer Gregory B.2ORCID,Duncan‐Azadi Cassandra3,Suzuki Yasuyuki4,Chiles Deborah5,Chime Sunring5,Chappell Phillip5ORCID

Affiliation:

1. Clinical Assistant Professor of Anesthesiology and Pain Management Department of Anesthesiology and Pain Management Children's Health System Texas Dallas Texas USA

2. Professor, Anesthesiology, Perioperative and Pain Medicine, and Pediatrics Stanford University Stanford California USA

3. Department of Anesthesiology Division of Pediatric Anesthesiology The University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA

4. Department of Critical Care and Anesthesia National Center for Child Health and Development Tokyo Japan

5. Post Approval Clinical Development Pfizer, Inc. New York New York USA

Abstract

AbstractBackgroundDexmedetomidine is a selective α2‐adrenergic agonist originally approved for sedation of adults in the intensive care unit and subsequently approved for procedural sedation in adults undergoing medical procedures. Dexmedetomidine is widely used off‐label for procedural sedation in children.AimsTo evaluate efficacy and safety of monotherapy dexmedetomidine for magnetic resonance imaging procedural sedation of children ≥1month–<17years across three ascending doses.MethodsRandomized, double‐blind, dose‐ranging study of procedural sedation recruited patients at USA and Japanese sites from February 2020 to November 2021. Patients were stratified into Cohort A (≥1month–<2years) or Cohort B (≥2–<17years). Cohort A loading doses/maintenance infusions: 0.5 mcg/kg/0.5 mcg/kg/h, 1.0 mcg/kg/1.0 mcg/kg/h, and 1.5 mcg/kg/1.5 mcg/kg/h. Cohort B loading doses/maintenance infusions: 0.5 mcg/kg/0.5 mcg/kg/h, 1.2 mcg/kg/1.0 mcg/kg/h, and 2.0 mcg/kg/1.5 mcg/kg/h. Primary endpoint was percentage of overall patients completing MRI without rescue propofol at the high versus low dose. Key secondary endpoint was percentage in each age cohort who did not require propofol at the high versus low dose.ResultsOne hundred twenty‐two patients received high‐ (n = 38), middle‐ (n = 42), or low‐dose (n = 42) dexmedetomidine. A greater percentage completed MRI without propofol rescue, while receiving high‐ versus low‐dose dexmedetomidine (24/38 [63.2%] vs. 6/42 [14.3%]) (odds ratio: 10.29, 95% confidence interval: 3.47–30.50, p < .001). Similar results were seen in both age cohorts. The most common adverse events were bradypnea, bradycardia, hypertension, and hypotension, and the majority were of mild‐to‐moderate severity.ConclusionsDexmedetomidine was well tolerated. The high dose was associated with meaningfully greater efficacy compared with lower doses. Based on these results, the recommended starting dose for procedural sedation in children ≥1month–<2years is loading dose 1.5 mcg/kg/maintenance infusion 1.5 mcg/kg/h; children ≥2–<17years is loading dose 2.0 mcg/kg/maintenance infusion 1.5 mcg/kg/h.

Funder

Pfizer

Publisher

Wiley

Reference18 articles.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3